We expect Moderna (MRNA) to launch multiple products in 2025, notes Lee Brown. He discusses vaccine stocks in focus. He talks about how MRNA posts a wider loss and cuts guidance as Covid vaccine sales drop. Brown also goes over how new RSV and flu vaccines are expected from MRNA. He expects MRNA to struggle to compete this year with GSK and PFE. He then looks at the outlook for weight loss drugs, highlighting Eli Lilly (LLY). Tune in to find out more about the stock market today.